Register of
Medicinal Products

Product class: Authorized package
Medicinal product class: For human use
Package code: 1716061
Name of medicinal product: CASPOFUNGIN TEVA GENERICS
Active substances:
Caspofungin
Estonian, English, Latin
ATC code: J02AX04
Dosage form: powder for concentrate for solution for infusion
Route of administration: intravenous use
Strengh: 70mg
Amount in package: 1TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: • Treatment of invasive candidiasis in adult or paediatric patients. • Treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy. • Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.
Safety features: Yes
Summary of product characteristics (SPC):  (last updated February 2, 2022)
Package information leaflet (PIL): EST  (last updated July 9, 2021)
Labelling:  (last updated July 9, 2021)
Last imported to Estonia: March 25, 2021
Marketing authorization holder: Teva B.V. 
Marketing authorization number: 932917 
Marketing authorization issued on: February 7, 2017 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Decentralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Description Additional condition
Hambaarstil on õigus välja kirjutada
Entry/Changing date: October 16, 2023
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere